Dipexium Pharmaceuticals Inc. is still sorting through data from a pair of identical phase III trials, but top-line findings in mild infections of diabetic foot ulcers with the company's lead – and only – product did nothing to encourage investors, and shares (NASDAQ:DPRX) tumbled 78 percent, or $9.95, to close Tuesday at $2.80. Read More
Global Blood Therapeutics Inc. (GBT) has reached an agreement with the FDA on the design of a pivotal phase III trial for GBT440, the company's experimental once-daily therapy for adults and adolescents with sickle cell disease (SCD). Read More
CLEVELAND – Funding for health care innovation remains robust, according to a panel of venture investors at the 2016 Medical Innovation Summit sponsored by Cleveland Clinic Innovations. Read More
By combining immunotherapy targeting the innate and adaptive immune systems, researchers have been able to eliminate large, established tumors in animal models. The four-component therapeutic strategy will "certainly not [be] trivial to translate," co-corresponding author Darrell Irvine told BioWorld Today. But the work is proof of principle that "there is some combination treatment in immunotherapy that allows the elimination of the majority of large tumors in animal models." Read More
HONG KONG – In an effort to encourage innovation and upgrade China's pharmaceutical sector, China's drug watchdog continues to target companies with weak clinical trial data. The latest example is the rejection of 30 new drug applications. Read More
PERTH, Australia – With only a handful of venture capital firms investing in the life sciences in Australia, the industry has had to look largely to the government for support. Read More
The FDA issued a direct rule, along with a proposed rule, that would ban medical products containing ozone-depleting substances (ODSs), including chlorofluorocarbons. Read More
Sunesis Pharmaceuticals Inc., of South San Francisco, closed its underwritten offerings of about 5.6 million shares of its common stock at a price of $3.85 per share, including the exercise in full of the underwriters' option to purchase additional shares at the public offering price, and 1,558 shares of its nonvoting series C convertible preferred stock at $3,850 per share. Read More
Immunomedics Inc., of Morris Plains, N.J., engaged Greenhill & Co. Inc. to serve as a strategic advisor primarily to assist in its ongoing efforts to out-license sacituzumab govitecan (IMMU-132), the company's lead investigational antibody-drug conjugate. (See BioWorld Today, June 6, 2016.) Read More
Ampliphi Biosciences Corp., of San Diego, reported top-line results from its phase I trial of AB-SA01, its phage cocktail targeting Staphylococcus aureus infections in patients with chronic rhinosinusitis. Read More
